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Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by
mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have
10% to 40% of the normal amount. Deletions in the dystrophin gene represent 65% of mutations in DMD/BMD patients. To
explain the contribution of immunohistochemical and genetic analysis in the diagnosis of these dystrophies, we present 10 cases
of DMD/BMD with particular features. We have analyzed the patients with immunohistochemical staining and PCR multiplex
to screen for exons deletions. Determination of the quantity and distribution of dystrophin by immunohistochemical staining
can conﬁrm the presence of dystrophinopathy and allows diﬀerentiation between DMD and BMD, but dystrophin staining is not
always conclusive in BMD. Therefore, only identiﬁcation involved mutation by genetic analysis can establish a correct diagnosis.
Copyright © 2009 Hanane Bellayou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The muscular dystrophy is a group of inherited disorders
characterized by progressive muscle weakness. The best
known are X-linked disorder Duchenne muscular dystrophy
(DMD) [MIM 310200] and Becker muscular dystrophy
(BMD) [MIM 300376]. DMD is the most common muscle
diseaseinchildren,withanincidenceofaround1in3500live
born males [1]. Aﬀected boys are usually wheelchair bound
by the age of 12 and die early in their third decade of life
from respiratory or cardiac failure. BMD is a milder form
of the disease with a later age of onset and a slower clinical
progression.
The DMD gene [MIM 300377] is the largest human gene
ever known, spanning 2.4Mb on Xp21 [2]. It consists of
79 exons and coding for dystrophin. 65% of DMD/BMD
cases show partial gene deletions (60%) or duplications
(5%) of diﬀerent sizes that are preferentially clustered in two
major hotspots of mutation, spanning exons 3–7 and 44–55.
Point mutations and small deletion/insertion account for the
remaining cases (35%) [3–5]. The diﬀerence between DMD
and BMD explained by the reading frame hypothesis, muta-
tions which disrupt the reading frame causing a premature
termination and loss of dystrophin, is leading to a severe
phenotype DMD. Mutations that retain the reading frame
generate a shortened protein; the dystrophin may still have
been limited to almost normal function, leading to a milder
phenotype BMD [6, 7].
The autosomal recessive limb-girdle muscular dystro-
phies (LGMD) (MIM 253700; MIM 600119; MIM 604286;2 Journal of Biomedicine and Biotechnology
MIM601287)areheterogeneousgroupofdisordersresulting
from mutation in any of four genes coding for the sarco-
glycan proteins α-, β-, γ-, and δ-sarcoglycans. The clinical
spectrum of LGMD or sarcoclycanopathies varies from
Duchenne-like to late-onset mild and slowly progressive
muscular dystrophy [8]. γ-sarcoglycanopathy is the most
commonsarcoglycanopathyintheNorthAfricanpopulation
due to a founder mutation, the 521delT in the γ-sarcoglycan
gene localized in 13q21 [9, 10].
The sarcoglcan proteins and dystrophin, are a part of the
large dystrophin-associated glycoproteins (DAGs) complex,
which is necessary for maintaining the link between the
cytoskeleton and the extracellular matrix and also essential
for preserving of the integrity of the muscle cell membrane
[11].
In DMD patients, immunohistoanalysis shows total
absence of dystrophin; whereas BMD patients have 10% to
40% of the normal amount or produce a partly functional
dystrophinproteinwithanalteredsize[12].Forpatientswith
sarcoglycanopathies, immunoﬂuorescence analyses showed
that absence or reduction in one of the sarcoglycan proteins
has consequences on the stability of the entire sarcoglycan
complex and sometimes reduction of dystrophin level as
well.
In order to reach a diagnosis and provide accurate
counsellingforpatients,andparticularlytheboys,aﬀectedby
severe muscular dystrophy, it is necessary to identify which
protein is primarily involved and thereby direct genetic
analysis accordingly.
The objective of this study is to report the contribution
of pathology and molecular genetics in diagnostic strategy
Duchenne and Becker muscular in Morocco and in the
diﬀerentiation between DMD and BMD. For that we expose
only 10 cases that represent a sample of all our patients with
some clinical, histopathological, and genetic features.
2.MaterialsandMethods
2.1. Patients. All patients were diagnosed in the neurological
departmentofCHUIbnRochd,Casablanca.Patientsshowed
progressive muscle weakness, calf hypertrophy, and elevated
serum creatine kinase levels (4–100 times the normal value).
Routine histological analysis of muscle biopsies revealed a
dystrophic myopathy in all cases.
2.2. Immunostaining. Muscle biopsies were analyzed
immunohistochemically using the mouse monoclonal
antibody Dys-C against C-terminal domain of dystrophin
and mouse monoclonal antibodies against α-a n dγ-
sarcoglycan (NovoCastra, Newcastle upon Tyne, UK), with
immunoperoxidase labeling [6, 13, 14].
2.3. Mutation Analysis. PCR deletion analysis of the dys-
trophin gene was performed by PCR multiplex with the
primer sets of Chamberlain et al. [15] and Beggs et al. [16].
The Chamberlain reaction uses primers for exons 45, 48,
19, 17, 51, 8, 12, 44, 4 and the Beggs reaction primers for
the muscular promoter and exons 3, 43, 50, 13, 6, 47, 60,
and 52. The PCR product was separated on 2% Nusieve+1%
agarose gel and detected in U.V light after ethidium bromide
staining. Deletions was diagnosed when one of the bands
present in the ampliﬁed control DNA was absent from the
patient DNA.
Screening for del521T mutation of the γ-sarcoglycan
gene was performed by PCR and directly sequenced. After
ampliﬁcation, 1μL samples were electrophresed using an
ABI PRISM 3130xl genetic analyzer (Applied Biosystems).
The data obtained were analyzed with GeneMapper analysis
software V3.2 (Applied Biosystems) according to the manu-
facturer’s recommendations.
3. Results and Discussion
We present an analysis of 10 boys with a muscular dystrophy;
they are still ambulant with calf hypertrophy and elevated
SCK activity. The patients underwent to immunohistochem-
istry analysis and molecular examinations (Table 1).
Contribution of the Immunohistochemical Investigation and
the Molecular Survey. On the basis of expression patterns
of dystrophin and γ-sarcoglycan, the patients were classiﬁed
into 4 groups.
The ﬁrst group, of 6 patients, showed complete absence
of dystrophin and normal expression of α-a n dγ-
sarcoglycans, suggesting DMD phenotype.
In the second group with 2 patients, the pattern consists
of an irregular Dys-C imunoreactivity with preservation of
α-a n dγ-sarcoglycans, usually determine a BMD phenotype.
In 7 patients of both groups, the deletions in dystrophin
gene were revealed by multiplex PCR. Patient 1 had a
maternal uncle with muscular dystrophy died after a cardiac
complication; and the mothers of patients 2 and 7 have
highSCKlevelssuggestingtheconductivemother.Moreover,
these3patientswerebornofanonconsanguineousmarriage,
all this information leads to an X-linked transmission, which
was subsequently conﬁrmed by immunohistochemistry and
genetic examinations. However, for patients 3 and 4, only
no consanguinity of parents can point to a possible X-
linked transmission. Whereas, for the patients 5 and 8,
with a ﬁrst degree of consanguinity and no similar cases
in the family, the immunohistochemical analysis directed
the molecular genetics investigation to conﬁrm diagnosis.
For the patient 6, no deletion was found. This patient
has an elder brother with the same symptoms and shows
no consanguinity. Therefore, further investigations should
be made to research the duplications or point mutations
on the dystrophin gene, since the family inquiry and the
immunohistochemical survey lead to a diagnosis of X-linked
dystrophinopathy.
In the third group (patient 9), signiﬁcant reduction of
Dys-C,α-andγ-sarcoglycansimmunoﬂuorescencewasseen,
indicating a dystrophinopathy, but such pattern has likewise
been observed in particular γ-sarcoglycanopathy. Since the
consanguinity of parents and the simplicity of the technique,
we searched the del521T in γ-sarcoglycan gene at ﬁrst, and
the mutation was not found. Subsequently, the multiplexJournal of Biomedicine and Biotechnology 3
Table 1: Clinical data, and genetic and immunohistochemical results for our patients.
N
◦ Age
(years)
Age at onset
(years) Consanguinity
Immunochemistry
Deleted exons Other criterion
Dys-C α-SG γ-SG
1 13 5 No − +++ +++ 50, 51, and 52 Elevated SCK activity at
the mother
2 93 N o − +++ +++ 45, 47, 48, 50,
51, and 52 Maternal uncle died
3 12 4 No − +++ +++ 51 and 52 Elevated SCK activity at
the mother
4 16 5 No − +++ +++ − Elder brother with the
same symptoms
5 11 3 Yes − +++ +++ 45 and 48 −
6 13 3 No − +++ +++ 45 −
7 12 5 No +/− +++ +++
12, 13, 17, 19,
43, 44, 45, 47,
and 48
—
8 13 5 Yes +/− +++ +++ 3, 4, 6, and 8 −
9 13 2 Yes + + + 48 521del T in γ-SG gene
not found
10 19 11 Yes +++ + + Pm 521del T in γ-SG gene
not found
+++: normal; +: reduced; +/−: irregular; − : absent
N◦: patient number; SG: sarcoglycan; Dys: dystrophin; SCK: serum creatine kinase.
12 3 4 5 6 7 8 91 01 1 12 13 14
15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31 32 33 34 35 36 37 38
39 40 41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60 61
62 64 65 66 67 68 69 70 72 73 74 75 76
77 78 79
DP427 DP427 muscle, cœur, cerveau et cervelet
DP260 R´ etine
DP427 cerveau, rein
DP427 cellules de Schwan
DP427 cerveau
Figure 1: Schematic representation of the 79 exons of dystrophin gene explains the reading frame rule of Monaco et al.
PCR identiﬁed the deletion of exon 48 in the dystrophin
gene.
In the latter group (patient 10), α-a n dγ-sarcoglycans
were severely reduced, and staining for Dys-C were clearly
detectable. This pattern related to γ-sarcoglycanopathy, in
addition, the clinical information indicates the autosomal
recessive trait and mild muscular dfystrophy. However;
the del521T has not been found in γ-sarcoglycan gene;
furthermore screening of the dystrophin gene revealed the
deletion of exon 1.4 Journal of Biomedicine and Biotechnology
The staining pattern of patient 9 was not speciﬁc for
BMD as it was also found in patients with α-a n dγ-
sarcoglycanopathy, thus the immunoanalysis is unable to
guidethecorrectmoleculargeneticanalysisinagivencase.In
addition, the immunohistochemical examination with Dys-
C antibody against the C-Terminal part of the dystrophin
alone can be misleading, as depicted in patient 10. There are
2 more antibodies; one is speciﬁc to the central domain and
theothertotheN-Terminalpartthatshouldbeusedtodirect
the genetic analysis accordingly. The immunohistochemistry
analysis is little quantitative and does not discern the
truncated proteins as well [17]. Therefore, the western blot
analysis, to consist on the separation of the proteins by their
molecular weights, which detect the truncated proteins, may
provide useful information in a given case of BMD [18].
In Duchenne and Becker muscular dystrophy, the clinical
examination determines the severity of dystrophy and mode
of transmission. Then, the recognition of protein deﬁciency
is important for guiding the genetic analysis directly to
the responsible gene, but in some cases, the immunohisto-
chemical analysis can be misdiagnosed (patients 9 and 10).
Therefore, only identiﬁcation of mutation can conclude a
correct diagnosis.
So far, we research the most frequent deletions at the
hotspot region, depicting 60% of the mutations incrimi-
nated, by multiplex PCR. Henceforth, a quantitative PCR
multiplex allows the simultaneous research of the deletions
and duplications in all exons.
Indeed, the deﬁnition of the deletion is necessary to
propose a genetic counselling and particularly prenatal
diagnosisforthefamily.Forfamilieswithoutdeletion,wecan
only propose linkage analysis using polymorphic markers to
female carriers.
The Correlation Genotype Phenotype DMD/BMD. The clin-
ical discrimination between DMD and BMD is linked to
the age at which the patient become weelchair dependent.
BMD patients remain ambulant until the age of 16, while
DMD patients are wheelchair dependent before the age of
13 years. When patients are younger than 12 years, it is
diﬃcult to establish a diagnosis. The immunohistochemical
investigation is the ﬁrst tool to guide diagnosis; irregular
or decreased expression of dystrophin suggests a BMD or
a γ-sarcoglycanopathy if the γ-sarcoglycan was also absent
(patients 7, 8, and 9). When the dystrophin was completely
absent, the diagnosis was still incomplete (patients 1, 2, 3, 4,
5, and 6).
T h er u l eo fM o n a c o[ 6] stipulates that the diﬀerence
between DMD and BMD depends on the reading frame
(Figure 1). If the mutation maintains an open reading frame,
a shortened but functional protein and a milder phenotype
(BMD) are observed. If the mutation shifts the translational
reading frame of the transcripts or creates a stop codon,
a severe phenotype (DMD) is observed and no protein is
present.
For patients 7, 8, and 9, the deletions maintain the
reading frame as they are not very large and are located in
the region coding for the central rod domain of dystrophin,
Exons
N54 7 8 10 6 1 3 9 2 N
Pm
3
43
50
13
6
47
60
52
Figure 2: Analysis of dystrophin gene by multiplex PCR. (The
primer sets of Chamberlain et al.). The top numbers correspond
to the codes of patients. The numbers at the right indicate the
ampliﬁed exons. N: Normal control with all exons. Patient 2 with
deletion of exons 50 and 52. Patient 1 with deletion of exons 50,
47, and 52. Patient 10 with deletion of promoter Pm. Patient 7 with
deletion of exon 52. Patient 4 with deletion of exons 3 and 6. Patient
5 with deletion of exons 43, 13, and 47.
Exons
45
48
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17
51
8
12
44
4
N547 8 10 6 1 3 9 2 N
Figure 3: Analysis of dystrophin gene by multiplex PCR. (The
primer sets of Beggs et al.). The top numbers correspond to the
codes of patients. The numbers at the right indicate the ampliﬁed
exons. N: Normal control with all exons. Patient 2 with deletion of
exon 51. Patient 9 with deletion of exon 48. Patient 3 with deletion
of exon 45. Patient 1 with deletion of exons 45, 48, and 51. Patient 8
with deletion of exons45 and 48. Patient 7 with deletion of exon 51.
Patient 4 with deletion of exons 8 and 4. Patient 5 with deletion of
exons 12, 19, 44, 45, 47, and 4.
that conﬁrms the results of immunoanalysis of a BMD. For
patients 1, 2, and 5, deletions disrupt the reading frame
conducting a DMD phenotype. For patient 3, deletion of
only exon 45 was found, with the presence of exons 44 and
47, in this casewe cannot conclude. Accordingly,the deletion
aﬀects or not exon 46; if it is deleted the reading frame will
be restoring and the BMD phenotype will appear (Figures 1
and 2).
For 4 and 10, the age of the patients indicates a BMD
diagnosis, since the patients are still ambulant. The deletion
o fe x o n s3 ,4 ,6 ,a n d8w a sf o u n di np a t i e n t4( F i g u r e s1 and
2). The reading frame is maintained, but this region presents
one of the exceptions to the rule of Monaco [19]. On the
region of exon 3 in exon 7, the deletion can produce bothJournal of Biomedicine and Biotechnology 5
phenotypes DMD and BMD. This patient of 16 years is still
ambulant suggesting a BMD diagnosis. For patient 10, the
deletion of exon 1 promoter was revealed. The expression
of dystrophin was preserved, that could be explained by the
presence of several more promoters in the dystrophin gene.
4. Conclusion
The protein-based strategy, followed by molecular analysis,
is probably the most logical and eﬃcient way to approach
diagnosis of Duchenne and Becker muscular dystrophy in
Morocco where sarcoglycanopathy DMD-like is the most
frequent muscular dystrophy.
However, complete immunohistochemistry analysis with
all available dystrophin antibodies, therefore, is a useful
tool to guide the molecular genetic investigations that are
necessary to arrive at the correct genetic diagnosis in a given
case.
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